

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

.....

Applicants :	Yukari Hirata et al.	.
Serial No. :	10/590,586	Case: BY0040P
Filed :	August 24, 2006	Art Unit: 1625
For :	Diaryl-Substituted Five-Membered Heterocycle Derivative	Examiner: D. Margaret Seaman

.....

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 C.F.R. 1.97, submitted on the attached form PTO/SB/08a is a list of patents, publications, applications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication, application or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Pursuant to 37 C.F.R. 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

Applicants respectfully request the Examiner initial the attached form PTO/SB/08a after reviewing the pertinence of each reference.

This Information Disclosure Statement is being filed within the time periods specified in 37 C.F.R. 1.97(b). Accordingly, it is believed that no fee is due. Any fees required in connection with this submission may be charged to Merck Deposit Account No. 13-2755.

Respectfully submitted,

By /J. Eric Thies, Reg.# 35382/
J. Eric Thies
Reg. No. 35,382
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3904

Date: October 9, 2009